Skip to content
HowShorted

Aimmune Therapeutics, Inc. short interest in 2019

In 2019, Aimmune Therapeutics, Inc.'s disclosed short interest ran from 10.92% of shares outstanding on 15 Jan 2019 to 17.17% on 31 Dec 2019, a change of +6.25 percentage points. The year's high was 23.02% on 30 Sep 2019 and its low 10.92% on 15 Jan 2019, averaging 16.45% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 27.86 days on 14 Jun 2019. Full history: Aimmune Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020

Aggregate net short position time series for Aimmune Therapeutics, Inc. in 2019

2019 in figures

Start of year
10.92% (15 Jan 2019)
End of year
17.17% (31 Dec 2019)
Change
+6.25 pp
High
23.02% (30 Sep 2019)
Low
10.92% (15 Jan 2019)
Average
16.45%
Highest days to cover
27.86 (14 Jun 2019)
SEC filings marked
8

Every report in 2019

Aimmune Therapeutics, Inc. short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 201910.92%8.75
31 Jan 201911.14%10.57
15 Feb 201911.82%11.41
28 Feb 201912.86%12.1910-K filed, results (8-K)
15 Mar 201914.96%13.05
29 Mar 201916.21%16.24
15 Apr 201916.81%18.55
30 Apr 201916.00%19.82
15 May 201915.14%16.6510-Q filed, results (8-K)
31 May 201915.85%22.73
14 Jun 201916.50%27.86
28 Jun 201916.26%21.62
15 Jul 201916.81%13.32
31 Jul 201917.15%22.62
15 Aug 201919.25%18.3910-Q filed, results (8-K)
30 Aug 201919.22%19.96
13 Sep 201919.39%7.97
30 Sep 201923.02%9.63
15 Oct 201918.22%8.56
31 Oct 201918.85%14.94
15 Nov 201916.57%16.9110-Q filed, results (8-K)
29 Nov 201917.28%14.61
13 Dec 201917.34%16.85
31 Dec 201917.17%14.31

See also: Aimmune Therapeutics, Inc.'s full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.